BAY 1436032

Drug Profile

BAY 1436032

Alternative Names: BAY1436032

Latest Information Update: 28 Apr 2017

Price : $50

At a glance

  • Originator Bayer
  • Class Antineoplastics
  • Mechanism of Action Isocitrate dehydrogenase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Acute myeloid leukaemia

Most Recent Events

  • 28 Apr 2017 Bayer plans a phase I trial for Acute myeloid leukaemia (Late-stage disease, Second-line therapy) in USA and Germany (NCT03127735)
  • 03 Dec 2016 Preclinical trials in Acute myeloid leukaemia in Germany (PO)
  • 03 Dec 2016 Pharmacodynamics data from preclinical studies in Acute myeloid leukemia presented at the 58th Annual Meeting and Exposition of the American Society of Haematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top